Our Experience and Literature Update Regarding Concomitant Radiotherapy with CDK4/6 Inhibitors and Hormonal Therapy in Metastatic Breast Cancer

Background and Objectives: Standard treatment in metastatic breast cancer with positive estrogen receptors and negative HER2neu is represented by CDK4 inhibitors combined with aromatase inhibitors or fulvestrant. Palliative radiotherapy is indicated for symptoms or local–regional control. Multiple p...

Full description

Bibliographic Details
Published in:	Journal of Mind and Medical Sciences
Main Authors:	Laura-Florentina Rebegea, Dorel Firescu, Oana-Gabriela Trifanescu, Roxana-Andreea Rahnea-Nita, Liviu Bilteanu, Mihaela Dumitru, Florentina Lacatus, Gabriela Rahnea-Nita
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Subjects:	CDK4/6 inhibitors toxicity metastatic breast cancer
Online Access:	https://www.mdpi.com/2392-7674/12/1/33

Similar Items

A Challenging Differential Diagnosis Between Brain Radionecrosis and Recurrent Metastatic Disease, with Temporary Clinical/Radiological Response to Bevacizumab and Later Imaging Suspicious for Oligoprogression
by: Ana Maria Rata, et al.
Published: (2026-03-01)

Anxiety and Depression in Advanced and Metastatic Lung Cancer Patients—Correlations with Performance Status and Type of Treatment
by: Roxana-Andreea Rahnea-Nita, et al.
Published: (2024-09-01)

Synchronous/Metachronous Prostate Cancer with Other Cancer Sites—The Experience of a Single Center in Romania
by: Gabriela Rahnea-Nita, et al.
Published: (2025-09-01)

Psychological Involvement in the Journey of a Patient with Localized Prostate Cancer—From Diagnosis to Treatment
by: Daniela Mihalcia Ailene, et al.
Published: (2025-10-01)

The role of radiotherapy in the complex treatment of mycosis fungoides; a case report
by: Laura Florentina Rebegea, et al.
Published: (2024-04-01)

Assessment of psycho-emotional symptoms in cancer patients in an Oncology-Palliative Care Department from Romania
by: Roxana Andreea Rahnea-Nita, et al.
Published: (2024-10-01)

The Efficacy of Immunotherapy in Long-Term Survival in Non-Small Cell Lung Cancer (NSCLC) Associated with the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
by: Roxana-Andreea Rahnea-Nita, et al.
Published: (2023-05-01)

The Benefits and Challenges of the Multimodal Treatment in Advanced/Metastatic Malignant Melanoma
by: Alexandru-Rares Stoian, et al.
Published: (2023-05-01)

Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
by: Zehra Sucuoğlu İşleyen, et al.
Published: (2025-07-01)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
by: Ioana-Miruna Stanciu, et al.
Published: (2023-03-01)

Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer
by: Loreto Domínguez Senín, et al.
Published: (2024-01-01)

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
by: Seda Kahraman, et al.
Published: (2024-12-01)

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania
by: Andreea-Iuliana Miron, et al.
Published: (2023-06-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

A Novel Integrated Perioperative Cardiovascular Risk Score (PERFORM-CV) in Non-Cardiac Surgical Patients
by: Andreea Boghean, et al.
Published: (2026-04-01)

The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis
by: Fausto Petrelli, et al.
Published: (2023-10-01)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
by: Viola Cogliati, et al.
Published: (2022-03-01)

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
by: Ioana-Miruna Stanciu, et al.
Published: (2023-04-01)

QT STAR: concomitant QTc-prolonging medication use among patients with HR+/HER2− metastatic breast cancer receiving a CDK4/6 inhibitor in first line
by: Susan Dent, et al.
Published: (2025-07-01)

A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
by: Albert Grinshpun, et al.
Published: (2020-06-01)

CDK5: an oncogene or an anti-oncogene: location location location
by: Kumar Nikhil, et al.
Published: (2023-11-01)

Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2− metastatic breast cancer in US routine clinical practice
by: Hope S. Rugo, et al.
Published: (2026-06-01)

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study
by: Sara M. Tolaney, et al.
Published: (2025-03-01)

Arcyriaflavin A, a cyclin D1/CDK4 inhibitor, suppresses tumor growth, migration, and invasion of metastatic melanoma cells
by: Dokyeong Kim, et al.
Published: (2025-02-01)

Identifying Cancers Impacted by CDK8/19
by: Igor B. Roninson, et al.
Published: (2019-08-01)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
by: Mridula A. George, et al.
Published: (2021-07-01)

Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis
by: Yuan Liu, et al.
Published: (2025-10-01)

Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
by: Yilan Yang, et al.
Published: (2025-02-01)

Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?
by: Merve Keskinkilic, et al.
Published: (2024-06-01)

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey
by: E. V. Artamonova, et al.
Published: (2021-01-01)

The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs
by: Amanda C. Sharko, et al.
Published: (2021-01-01)

CDK4/6 Inhibition and Stereotactic Radiotherapy in Oligometastatic HR+/HER2− Breast Cancer: Evidence of Immunogenic Modulation and Pseudoprogression
by: Andrea Emanuele Guerini, et al.
Published: (2026-06-01)

Reinitiating Chemotherapy beyond Progression after Maintenance Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
by: Roxana-Andreea Rahnea-Nita, et al.
Published: (2024-07-01)

CDK8-Novel Therapeutic Opportunities
by: Ingeborg Menzl, et al.
Published: (2019-06-01)

Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay
by: Jing Li, et al.
Published: (2019-10-01)

CDK12/CDK13: New Hope for Targeted Therapy of Human Malignant Tumors
by: CHEN Kaixing, et al.
Published: (2024-05-01)

Role of pre-metastatic niche in organ specificity of breast cancer metastasis. Influence on metastatic potential as a basis for CDK4/6-inhibition efficacy in early therapy of disseminated hormone-receptor-positive disease
by: A. I. Stukan, et al.
Published: (2021-12-01)

Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
by: Ioannis A. Voutsadakis
Published: (2025-06-01)